Zoetis
Advancing animal health care
- B2B
- B2C
- Has physical offices
- Publicly traded
- Manufacturing
- Multi-product
- Sales-led purchase
About Zoetis
A global leader in animal health, focused on advancing care for animals through medicines, vaccines, diagnostics, and technologies in over 100 countries
Key facts
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,000+ employees
- Headquarters
- Parsippany, New Jersey, United States
- Founded
- 2013
- Revenue
- $9.5BFY2025, publicly reported
- Website
- zoetis.com
- linkedin.com/company/zoetis
Jobs at Zoetis
- Senior Manager, EHS & Sustainability Site Leader
- Facilities & Production Maintenance Technician
- Manufacturing Technician – Vaccine Production | Weekend Shift
- Manufacturing Technician - Vaccine Production | Weekend Shift
- Sr Mgr HRBP - US Petcare and Global Diagnostics
- Associate Director, Global Animal Behavior
- Manufacturing Technician – Vaccine Production | 1st Shift
- O2C Junior Global Process Owner GPO (m/f/x)
Zoetis in the news
- Michael Burry Sells FLUT To Pile Into LULU Under $100 — Plus A New Bet On ZTS
Investor Michael Burry sold Flutter Entertainment, bought Lululemon Athletica under $100, and increased his stake in Zoetis Inc., citing valuation opportunities and potential management changes.
- What Is Drawing Fresh Attention To Zoetis (ZTS)?
Zoetis stock has experienced significant declines following a reduced 2026 outlook and faces mixed investor sentiment regarding its valuation, growth prospects, and financial risks.
- Zoetis Stock (ZTS) Opinions on Michael Burry Portfolio Update
Discussions surrounding Michael Burry's portfolio inclusion of Zoetis highlight its stable demand despite recent growth moderation and a stock price drop, with mixed insider, congressional, and hedge fund activity alongside a median analyst price target of $99.0.
- Zoetis Inc. stock underperforms Tuesday when compared to competitors
Zoetis Inc. stock performed poorly on Tuesday compared to its competitors.
- Zoetis (ZTS) Shares Drop After Earnings Revision
Zoetis Inc. (NYSE: ZTS) shares dropped after an earnings revision and concerns over its canine arthritis product, Librela, impacting its performance in the Impax US Sustainable Economy Fund.
Zoetis at a glance
Zoetis is a B2B/B2C company in the Pharmaceutical Manufacturing industry, headquartered in Parsippany, New Jersey, United States.
Zoetis was founded in 2013.
Zoetis has 10,000+ employees.
Zoetis's revenue is $9.5B (FY2025, publicly reported).
Zoetis is hiring: 8 recent open roles, including Senior Manager, EHS & Sustainability Site Leader, Facilities & Production Maintenance Technician, Manufacturing Technician – Vaccine Production | Weekend Shift.
Selling to companies like Zoetis?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies